Table 3. The characteristics of included studies.
| First author | Year | Country | Ethnicity | Study type | Genotyping method | Case/control | Cases' characteristics | Controls' characteristics | ||||
| Male/female ratio | Mean age (SD) | Family history of cancer | Male/female ratio | Mean age (SD) | Control source | |||||||
| Tenesa A (Scotland 1) | 2008 | Scotland | European | GWAS | Illumina | 3004/3094 | – | – | – | – | – | Population based |
| Tenesa A (Scotland 2) | 2008 | Scotland | European | Replication | TaqMan | 937/941 | – | – | – | – | – | Population based |
| Tenesa A (Canada) | 2008 | Canada | European | Replication | TaqMan, Sequenom | 1175/1184 | – | – | – | – | – | Population based |
| Tenesa A (DACHS) | 2008 | German | European | Replication | TaqMan | 1373/1480 | – | – | – | – | – | Population based |
| Tenesa A (England) | 2008 | England | European | Replication | TaqMan | 2253/2262 | – | – | – | – | – | Population based |
| Tenesa A (Israel) | 2008 | Israel | European | Replication | TaqMan | 1789/1771 | – | – | – | – | – | Population based |
| Tenesa A (Japan) | 2008 | Japan | Asian | Replication | Invader assay | 4400/3179 | – | – | – | – | – | – |
| Tenesa A (Kiel) | 2008 | German | European | Replication | TaqMan | 2169/2145 | – | – | – | – | – | Population based |
| Tenesa A (Spain) | 2008 | Spain | European | Replication | TaqMan | 357/297 | – | – | – | – | – | Hospital based |
| Pittman AM (CORGI) | 2008 | England | European | GWAS | Illumina | 619/932 | 0.82 | – | Yes | 0.87 | – | Population based |
| Pittman AM (DFCCS) | 2008 | Netherlands | European | Replication | KASPar | 783/664 | 0.90 | 53.4 (13.4) | Yes | 0.61 | 51.1 (11.3) | Population based |
| Pittman AM (EPICOLON) | 2008 | Spain | European | Replication | Sequenom iPLEX | 515/515 | 1.45 | 70.6 (11.3) | No | 1.29 | 69.8 (11.7) | Hospital based |
| Pittman AM (FCCPS) | 2008 | Finland | European | Replication | KASPar | 1001/1034 | 1.03 | 67.4 (11.8) | – | – | – | Population based |
| Pittman AM (MCCS) | 2008 | Australia | European | Replication | HRM | 515/709 | 1.10 | 66.2 (7.7) | – | 0.99 | 57.9 (7.0) | Population based |
| Pittman AM (NSCCG1) | 2008 | England | European | GWAS | Illumina | 2863/2838 | 0.72 | 59.3 (8.7) | – | 0.67 | 59.8 (10.8) | Population based |
| Pittman AM (NSCCG2) | 2008 | England | European | Replication | KASPar | 3036/2944 | 1.16 | 59.4 (8.2) | – | 0.67 | 55.2 (12.3) | Population based |
| Pittman AM (VCQ) | 2008 | England | European | Replication | KASPar, | 1251/799 | 0.89 | – | – | 0.73 | – | Population based |
| Middeldorp Aac | 2009 | Netherlands | European | Replication | KASPar | 995/1340 | 0.92 | – | Yes | 0.90 | – | Population based |
| Wijnen JTa | 2009 | Netherlands | European | Replication | KASPar | 131/544 | 1.43 | – | – | 0.70 | – | Population based |
| Kupfer SS (Combined African-American)b | 2010 | America | African | Replication | MassARRAY | 795/985 | 0.88 | 64.5 (11.7) | – | 0.72 | 62.3 (13.2) | Population based |
| Kupfer SS (European-American)b | 2010 | America | European | Replication | MassARRAY | 399/367 | 1.35 | 64.6 (13.1) | – | 1.01 | 61.1 (12.7) | Population based |
| Von Holst S | 2010 | Sweden | European | Replication | DeCode test | 1786/1749 | 1.13 | 68.6 | 22%d | – | 66.3 | Population based |
| Xiong F | 2010 | China | Asian | Replication | PCR-RFLP | 2124/2124 | 1.48 | 56.9 (11.8) | – | 1.4 | 56.4 (11.3) | Population based |
| Talseth-Palmer BAa | 2010 | Australia,Poland | European | Replication | Real-Time PCR | 262/314 | – | – | – | – | – | Hospital based |
| He J (European American)b | 2011 | America | European | Replication | TaqMan | 1171/1534 | – | – | – | – | – | – |
| He J (African American)b | 2011 | America | African | Replication | TaqMan | 382/510 | – | – | – | – | – | – |
| He J (Native Hawaiian)b | 2011 | America | European | Replication | TaqMan | 323/472 | – | – | – | – | – | – |
| He J (Japanese American)b | 2011 | America | Asian | Replication | TaqMan | 1042/1426 | – | – | – | – | – | – |
| He J (Latinos)b | 2011 | America | European | Replication | TaqMan | 393/524 | – | – | – | – | – | – |
| Ho JW | 2011 | HK, China | Asian | Replication | Sequenom | 892/890 | 1.64 | 66.75 (12.25) | – | – | – | Hospital based |
| Mates IN | 2012 | Romania | European | Replication | DeCode test | 153/182 | 0.99 | 67.9 (11.2) | 15.7% d | 3.92 | 60.8 (14.7) | Hospital based |
| Current study | 2012 | China | Asian | Replication | TaqMan | 641/1037 | 1.49 | 56.31 (12.59) | – | 1.45 | 57.24 (10.86) | Population based |
Abbreviations: GWAS, genome-wide association studies; SD, standard deviation; HRM, high resolution melt curve analysis.
a
The study included some Lynch syndrome patients.
b
The study only provided an adjusted additive OR.
c
The study only provided an allelic OR.
d
The percentage of patients having a family history of cancer.